New combo therapy aims to halt rare gynecologic cancer
NCT ID NCT05559879
First seen Apr 17, 2026 · Last updated Jun 14, 2026 · Updated 10 times
Summary
This study tests whether combining two drugs—cabozantinib and dostarlimab—can help women with a rare and aggressive gynecologic cancer called carcinosarcoma that has come back after initial treatment. About 37 participants will receive the combination therapy. The main goal is to see how many remain cancer-free for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
O'Neal Comprehensive Cancer Center at UAB
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.